Anti-epidermal growth factor receptor (EGFR) antibodies
Provided are anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-EGFR antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects.
1. An anti-epidermal growth factor receptor (EGFR) antibody comprising:
a) a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 32, and a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 38;
b) a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 32, and a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 37;
c) a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 33, and a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 36;
d) a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 34, and a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 36; or
e) a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 35, and a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 39.
2. The anti-EGFR antibody of claim 1 , comprising a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 32, and a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 38.
3. The anti-EGFR antibody of claim 1 , comprising a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 32, and a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 37.
4. The anti-EGFR antibody of claim 1 , comprising a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 33, and a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 36.
5. The anti-EGFR antibody of claim 1 , comprising a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 34, and a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 36.
6. The anti-EGFR antibody of claim 1 , comprising a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 35, and a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 39.
7. The anti-EGFR antibody of claim 1 , wherein the antibody comprises a Fc sequence of a human IgG.
8. The anti-EGFR antibody of claim 1 , wherein the antibody is in a form of a Fab, a Fab′, a F(ab)′2, a single-chain Fv (scFv), a Fv fragment, a diabody or a linear antibody.
9. The anti-EGFR antibody of claim 1 , wherein the antibody is a multispecific antibody.
10. The anti-EGFR antibody of claim 1 , wherein the antibody is an afucosylated antibody.
11. The anti-EGFR antibody of claim 1 , wherein the antibody is conjugated to a therapeutic agent.
12. The anti-EGFR antibody of claim 1 , wherein the antibody is conjugated to a label.
13. The anti-EGFR antibody of claim 12 , wherein the label is selected from the group consisting of a radioisotope, a fluorescent dye and an enzyme.
14. A composition comprising the anti-EGFR antibody of claim 1 and a pharmaceutically acceptable carrier.